Plain-English translation of NCT06414902 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new imaging scan called 18F-AraG PET to help predict whether people with esophageal cancer will respond well to chemotherapy combined with radiation. Doctors already use similar scans to monitor cancer, but this new one may be better at showing early signs of how well the treatment is working. The study will help determine if this scan can become a standard tool to guide treatment decisions.
Currently, doctors have limited ways to quickly tell if esophageal cancer treatment is working, and they often have to wait until after treatment is finished to see results. This new imaging scan could help detect treatment response much earlier, which might allow doctors to adjust care plans sooner if needed.
You likely qualify if…
You likely don't qualify if…
You will receive the standard imaging scans your doctor normally orders before treatment starts. Then, as part of this study, you will have an additional 18F-AraG PET scan. Before the scan, you'll drink about 16 ounces of water to help the imaging tracer clear through your kidneys, and then the tracer will be injected into your bloodstream. The study team will also collect blood and tissue samples to compare with the imaging results.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
M.D. Anderson Cancer Center
Enrollment target
~60 participants
Started
September 2024
Primary completion
October 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Steven Lin, MD
M.D. Anderson Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.